Pfizer Inc. (NYSE:PFE) Stock Position Decreased by Zions Bancorporation N.A.

Zions Bancorporation N.A. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 3.4% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 210,629 shares of the biopharmaceutical company’s stock after selling 7,318 shares during the period. Zions Bancorporation N.A.’s holdings in Pfizer were worth $5,893,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PFE. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Pfizer during the 4th quarter valued at approximately $16,166,000. LGT Group Foundation lifted its stake in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares during the last quarter. First Heartland Consultants Inc. boosted its holdings in shares of Pfizer by 43.3% during the fourth quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 3,933 shares during the period. ORG Partners LLC grew its position in shares of Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after acquiring an additional 44,458 shares during the last quarter. Finally, Kempner Capital Management Inc. acquired a new stake in shares of Pfizer in the 1st quarter worth about $2,439,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. UBS Group raised their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Finally, Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Trading Down 1.7 %

Shares of PFE stock opened at $29.16 on Friday. The stock has a 50-day simple moving average of $29.19 and a 200 day simple moving average of $28.10. The stock has a market capitalization of $165.24 billion, a P/E ratio of -485.92, a P/E/G ratio of 1.04 and a beta of 0.68. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.62. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. During the same quarter last year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.76%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.